A Comparative Study of Lipid Profile in Chronic Renal Failure Patients on Dialysis
DOI:
https://doi.org/10.48112/acmr.v1i1.6Keywords:
Chronic renal failure, triglycerides, CVD, dialysisAbstract
Abstract Views: 38
Chronic renal failure (CRF) is characterized by loss of kidney function due to lasting damage to nephrons resulting in decreased estimated glomerular filtration (eGFR) and suppressed urine formation. Disturbance of lipid profile in CRF has been found associated with increased triglycerides (TG) and low high-density lipids while the normal level of total cholesterol (TC) and low-density lipids (LDL). Dislipidemia in CRF patients induces cardiovascular diseases (CVD); in addition, CVD in turn leads to the more rapid destruction of the kidney. Therefore the present study was designed to evaluate the lipid profile in CRF patients with and without dialysis. This was a prospective type of study conducted in the Department of Medicine of a tertiary care centre from July 2019 to December 2019. A total of 100 patients of CRF patients and 40 normal control subjects were recruited for the study. CRF patients were divided into two groups. Group, I consisted of CRF patients with dialysis and group II included CRF patients without dialysis. Normal subjects were kept under a group III control group. The study revealed that there was a significant difference between TG, HDL and VLDL of group I (p>0.01) and group II (p>0.01) in comparison to group III. On the other hand, no significant variation was seen in the TC and LDL levels of the groups mentioned. CRF patients either with dialysis or without dialysis have a great possibility of developing dyslipidemia as well as CVD. Dialysis has been found effective in reducing nitrogenous waste products in the blood; however, it is not able to decrease the lipid profile in CRF patients.
References
Dewardener HE. An outline of normal and abnormal function. In: The kidney. (pp. 181-235) 1986.
Mathenge RN, Mcligego SO, Mutua AK, Otieno L. S The spectrum of echocardiographic finding in chronic renal failure. East Afr Med J. 2003;70(3):97–103.
Moronkola OA, Ojediran MM, Amosu A. Menstrual disorder in chronic renal failure patients attending renal clinics in Ibadan. Nigeria. African Health Sciences 2006;6(3):155–160.
Ravichandran R. Hyperlipidemia in patients with chronic renal failure. J Postgrad Med. 1983;29(4):212–217.
ASF., ed. Harrison’s Principles of Internal Medicine. USA: The McGraw Hill's. (pp. 275).
Amin. Pattern of Dyslipidemia in patients with CRF. Professional Med J Mar. 2006;13(1):79–84.
Dumm NTdG, Giammona AM, Touceda LA. Variations in the Lipid Profile of Patients with Chronic Renal Failure, Treated with Folic Acid. Int J Vitam Nutr Res. 2003;73(3):215–220. Available from: https://dx.doi.org/10.1024/0300-9831.73.3.215
Brosnahan G, Fraer M. Chronic Kidney Disease: Whom to Screen and How to Treat, Part 1: Definition, Epidemiology, and Laboratory Testing. South Med J. 2010;103(2):140–146. Available from: https://dx.doi.org/10.1097/smj.0b013e3181c99438
Burtis CA, Ashwood ER, Bruns DE.
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge. Clin Chem. 1972;18(6):499–502. Available from: https://dx.doi.org/10.1093/clinchem/18.6.499
Agarwal SK, Srivastava RK. Chronic Kidney Disease in India: Challenges and Solutions. Nephron Clin Pract. 2009;111(3):197–203. Available from: https://doi.org/10.1159/000199460
VAZIRI ND, MORADI H. Mechanisms of dyslipidemia of chronic renal failure. Hemodial Int. 2006;10(1):1–7. Available from: https://dx.doi.org/10.1111/j.1542-4758.2006.01168.x
Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol. 2006;290(2):262–272. Available from: https://dx.doi.org/10.1152/ajprenal.00099.2005
Saland JM, Ginsberg HN. Lipoprotein metabolism in chronic renal insufficiency. Pediatr Nephrol. 2007;22(8):1095–1112. Available from: https://dx.doi.org/10.1007/s00467-007-0467-5
Ekonoyan G. On the epidemic of cardiovascular disease in patients with chronic renal disease and progressive renal failure: a first step to improve the outcomes. Am J Kidney Dis. 1998;32:3–5. Available from: https://doi.org/10.1053/ajkd.1998.v32.pm9820462
Gupta DK. Hyperlipidaemia in a patient with chronic renal failure. Bombay Hosp J. 1990;33:45–50. Available from: https://doi.org/10.1159/000170146
Das BS, Mishra SK, Rao DP. Serum lipid abnormalities in Ureamia. Kidney Int. 1988;19:625–637.
Zoccali C. Cardiovascular risk in uraemic patients—is it fully explained by classical risk factors? Nephrol Dia Transpl. 2000;15:454–457. Available from: https://doi.org/10.1093/ndt/15.4.454
Chan MK, Verghese, Morehead JF. Lipid abnormalities in ureamia. Kidney International 1988;19:625–637.
Janicki. Abnormal lipoprotein metabolism in hemodialysis patients. Annales Universitatis Mariae Curie - Skłodowska Lublin- Polonia 2007.
Reddy EP. Dyslipidemia: End-Stage Renal Disease and Hemodialysis. The Internet Journal of Nephrology 2009;5(1).
Senti M, Romero R, Pedro-Botet J, Pelegrí A, Nogués X, Rubiés-Prat J. Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure. Kidney Int. 1992;41(5):1394–1399. Available from: https://dx.doi.org/10.1038/ki.1992.204
Elisaf M. Atherogenic lipid and lipoprotein parameters in hemodialysis patients. Dial Trans 1995;24:642–60.
Ponticelli C. Lipid abnormalities in maintenance dialysis patients and renal transplant patients. Kidney Int. 1978;13:572–580. Available from: https://dx.doi.org/10.5527%2Fwjn.v4.i1.83
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Advances in Clinical Medical Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
OAI-PMH 
